Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.31 USD | +6.45% | +10.00% | -66.62% |
Apr. 29 | Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment | MT |
Apr. 18 | Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.62% | 60.99M | |
-3.73% | 87.06B | |
+2.76% | 40.25B | |
-17.49% | 31.09B | |
+54.44% | 24.74B | |
-13.13% | 15.91B | |
-9.12% | 11.96B | |
-15.45% | 11.92B | |
-42.56% | 11.61B | |
+4.87% | 8.73B |
- Stock Market
- Equities
- IMMX Stock
- News Immix Biopharma, Inc.
- Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year